MDNA.TO: End-of-Phase 2 Meeting with FDA for MDNA55 in 1Q20…
By David Bautz, PhD
TSX:MDNA.TO | OTC:MDNAF
READ THE FULL MDNA.TO RESEARCH REPORT
Highly Encouraging Results for MDNA55 When Comparing with Synthetic Control Arm
On January 13, 2020, Medicenna Therapeutics Corp. (TSX:MDNA.TO) (OTC:MDNAF) announced encouraging data for the company’s Phase 2b clinical trial of MDNA55, an IL-4 targeted toxin, in patients with recurrent glioblastoma (rGBM) when compared to an eligibility-matched arm of control subjects (n=81) who were treated with approved therapies, including Avastin®, lomustine, and temozolomide. The control subjects had similar baseline features as patients treated with MDNA55 including de novo grade IV GBM at 1st or 2nd relapse following standard 1st-line treatments with surgery and radio-chemotherapy, tumors between 1 cm ...